title: Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
abstract: Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line, K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML.
authors.forename: Seiichi
authors.initials: S
authors.lastname: Okabe
authors.forename: Tetsuzo
authors.initials: T
authors.lastname: Tauchi
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; C060902:lyn protein-tyrosine kinase; D019061:src-Family Kinases; C498826:nilotinib; D000069439:Dasatinib